Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the prevalence of alopecia areata in Japan increased from 2012 to 2019, with allergic diseases as common comorbidities and a need for more effective treatments, particularly for severe and pediatric cases.

This study found that pentoxifylline plus topical corticosteroids had the highest treatment success rate for alopecia areata compared to no treatment, but the best overall treatment remains uncertain due to varying data.

This study in Japan identified an estimated prevalence of alopecia areata between 1.45% and 2.18%, highlighting a significant psychological burden and potential unmet need for treatment among affected individuals.

This study highlights that dermoscopy is an essential, non-invasive tool for diagnosing and monitoring alopecia areata, with various dermoscopic patterns associated with disease severity and activity, but also emphasizes the need for improved topical therapies and standardized criteria, especially for diverse populations.

This retrospective study described the demographic characteristics, treatments, and prognosis of children with alopecia areata in a clinical setting, reporting a remission rate of 34.5% and highlighting the need for more comprehensive epidemiological data in this population.

This study found that topical corticosteroids are the most supported first-line treatment for pediatric alopecia areata, with contact immunotherapy as the next best option.

This review of alopecia areata cases at Virgen Macarena University Hospital identified a new hair regrowth pattern they term "androgenetic alopecia type" and described a unique inverse form called "sisaipho type" in three cases.

This review discusses current and emerging therapies for alopecia areata, highlights the challenges in managing this chronic disease, and emphasizes the importance of addressing its psychosocial impacts; it reports no new clinical results.

This case report describes a unique presentation of frontal fibrosing alopecia characterized by a hair loss pattern that resembles the Greek letter upsilon, supported by trichoscopic and histological findings.

This review discusses the assessment and management of common causes of pediatric alopecia, highlighting the importance of dermatologist referral for unclear diagnoses, treatment failures, or scarring alopecia, and reports no new clinical findings.

This review synthesizes current evidence on alopecia areata, detailing its clinical features, pathogenesis, and treatment options, but does not present new clinical results.

In this study, researchers retrospectively analyzed five children with extensive and refractory alopecia areata treated with mesalazine, observing complete hair regrowth in all patients without side effects, suggesting potential benefits of this treatment combination, though controlled studies are needed for confirmation.

This review discusses the genetics, therapy, and prognosis of childhood alopecia areata, noting that while current treatments are not curative, new modalities may improve future outcomes; it reports no new clinical results.

This case study describes severe hypertrichosis in a 3-year-old with alopecia areata after unsupervised use of high-dose topical minoxidil, highlighting the need to avoid such practices in children.

This article outlines treatment options and counseling recommendations for pediatric alopecia areata, highlighting shared decision-making based on disease severity and patient goals, with newer treatments like JAK inhibitors and dupilumab requiring attention to cost and side effects.

This review discusses recent advances in understanding and treating alopecia areata, emphasizing the ongoing challenges and unmet needs in disease management; it reports no new clinical findings.

This source reports that platelet-rich plasma may be as effective as intralesional corticosteroids for treating patchy alopecia areata, with potential for earlier and more sustained results, while promising in vitro and animal studies on stem cells highlight the need for more clinical research.

This case report observed marked hair regrowth in a patient with refractory alopecia areata using a combination of platelet-rich plasma, low-level light therapy, and microneedling alongside topical and oral agents.

In this case report, a 39-year-old man with sudden whitening of scalp hair due to alopecia areata experienced total regrowth of pigmented hair after six months without systemic treatment.

This study found that there was no significant difference in hair regrowth between clobetasol and bimatoprost for scalp alopecia areata over 12 weeks, but bimatoprost had fewer side effects and prompted earlier, more pigmented hair regrowth.

This review discusses prevention, diagnosis, and treatment strategies for traction alopecia but presents no new clinical findings; the authors emphasize early intervention to prevent permanent hair loss.

This abstract presents a patient case study and does not report new research findings.

In this overview, the authors note that both pharmacologic and nonpharmacologic treatments are effective for pattern hair loss, emphasizing early detection and intervention to maintain hair.

This consensus from the Taiwanese Dermatological Association suggests that for mild to moderate alopecia areata, first-line treatments may include topical or intralesional corticosteroids, possibly with topical minoxidil, while severe cases might require systemic corticosteroids or Janus kinase inhibitors.

This study observed that alopecia areata in children often presents as mild scalp patches, with the majority showing some hair regrowth following treatment, particularly when using potent topical steroids, which were most commonly prescribed in the reviewed cases.

This consensus statement from Saudi Arabia outlines evidence- and experience-based recommendations for diagnosing and managing alopecia areata, focusing on severity assessment, prognostic indicators, and therapeutic options, with special attention to pediatric patients and uncommon cases.

This review article reports recent advancements in understanding, diagnosing, and treating various hair loss conditions, like androgenetic alopecia and alopecia areata, including their genetic factors and new therapeutic options, while also examining the impact of COVID-19 on hair loss.

This paper presents an interactive quiz related to a study by Deng et al. (2022) in the Journal of Investigative Dermatology, examining androgen receptor-mediated paracrine signaling in androgenetic alopecia, but it provides no new clinical findings.

This study found that methylprednisolone pulse therapy may be an effective treatment option for patients with severe multifocal alopecia areata, particularly those experiencing their first episode.

This study described cases of alopecia areata occurring after COVID-19 vaccination and highlights management using both topical and systemic therapies.